Univariable and multivariable logistic regression analysis of variables associated with positive Aspergillus BAL cultures at age 5 years
| Univariable logistic regression | ∆OFV | OR (95% CI) |
| Categorical variable | ||
| Female | −1.77 | 0.57 (0.06 to 1.48) |
| Meconium ileus | −0.41 | 1.37 (0.48 to 5.81) |
| Children in BAL arm of ACFBAL study | −0.88 | 1.07 (0.47 to 2.41) |
| Received gentamicin | −0.01 | 1.06 (0.25 to 3.13) |
| Received anti-staphylococcal prophylaxis until their first birthday | −2.53 | 0.48 (0.30 to 5.32) |
| Continuous variables | ||
| Body mass index z-score at BAL | −0.65 | 0.89 (0.44 to 1.59) |
| Cumulative dosage of intravenous tobramycin received (mg)* | −9.19 | 1.08 (0.99 to 1.10) |
| Cumulative dosage of inhaled tobramycin received (mg)* | −2.88 | 1.00 (0.99 to 1.01) |
| Cumulative dosage of intravenous tobramycin (not associated with eradication therapy) (mg) | −3.42 | 1.12 (1.00 to 1.12) |
| Cumulative dosage of intravenous and oral antibiotics (not associated with eradication therapy) (mg)† | −0.77 | 1.00 (1.00,1.00) |
| Minimum annual temperature at geographic region at baseline (°C) | −2.07 | 0.96 (0.83 to 0.99) |
| Maximum annual temperature at geographic region at baseline (°C) | −3.89 | 1.09 (1.01 to 1.17) |
| Discrete variables | ||
| Number of Pseudomonas aeruginosa eradication therapy courses received before BAL‡ | −14.55 | 1.61 (1.23 to 2.12) |
| Number of ‘all-cause’ CF-related hospitalisations before age 5 years BAL | −3.94 | 1.11 (0.78 to 1.24) |
| Number of pulmonary exacerbations requiring hospitalisation before age 5 years BAL | −0.06 | 1.00 (0.86 to 1.06) |
| Number of all pulmonary exacerbations before age 5 years BAL | −0.66 | 0.92 (0.9 to 1.07) |
| Multivariable logistic regression | ||
| Base model+number of P. aeruginosa eradication therapy courses received before BAL positive cultures for Aspergillus | ∆OFV | OR (95% CI) |
| Cumulative dosage of intravenous tobramycin received (mg) | −0.43§ | 1.02 (0.95 to 1.09) |
| Number of ‘all-cause’ CF-related hospitalisations before age 5 years BAL | −0.03§ | 1.01 (0.98 to 1.02) |
| Cumulative dosage of intravenous tobramycin (not associated with eradication therapy) (mg) | −0.10§ | 1.01 (1.00 to 1.01) |
| Maximum annual temperature of geographic location at baseline (°C) | −4.56§ | 1.11 (1.01 to 1.20)¶ |
| Final model | ||
| Base model+number of P. aer uginosa eradication therapy courses received before age 5 years BAL | −14.55 1.61 (1.23 to 2.12)** | |
*Combined with an anti-pseudomonal beta-lactam antibiotic.
†Antibiotics other than tobramycin and not associated with eradication therapy (eg, intravenous cefuroxime, oral macrolides, amoxicillin-clavulanate and co-trimoxazole).
‡Model carried forward from the univariable step to the multivariable step.
§Based on (Base+number of P. aeruginosa eradication therapy courses received before BAL).
¶Excluded from the final model during backward elimination step as p>0.01.
**Bootstrap results (95% CI).
ACFBAL, Australasian Cystic Fibrosis Bronchoalveolar Lavage study; BAL, bronchoalveolar lavage; CF, cystic fibrosis; ∆OFV, change in objective function value.